Cart
sales@molnova.com
HAP-12
CAS No. 1078164-85-8
HAP-12( HAP12 )
Catalog No. M10314 CAS No. 1078164-85-8
HAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 100MG | Get Quote | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameHAP-12
-
NoteResearch use only, not for human use.
-
Brief DescriptionHAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM.
-
DescriptionHAP-12 is a small molecule HBV capsid assembly effector that inhibits HBV DNA replication with EC50 of 0.5 uM.
-
In Vitro——
-
In Vivo——
-
SynonymsHAP12
-
PathwayMicrobiology/Virology
-
TargetHBV
-
RecptorHBV
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1078164-85-8
-
Formula Weight444.891
-
Molecular FormulaC22H22ClFN4O3
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Namemethyl 4-(2-chloro-4-fluorophenyl)-6-(morpholinomethyl)-2-(pyridin-2-yl)-1,4-dihydropyrimidine-5-carboxylate
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Boucle S, et al. Bioorg Med Chem Lett. 2017 Feb 15;27(4):904-910.
molnova catalog
related products
-
GLP-26
GLP-26 is a novel potent HBV capsid modulator that reduces secreted HBeAg in HepNTCPDL cells transfected with HBV wild type with EC50 of 0.7 uM.
-
ccc_R08
ccc_R08 is an orally available HBV cccDNA inhibitor that reduces extracellular levels of HBV DNA, HBsAg, and HBeAg in a dose-dependent manner. ccc_R08 is investigational for use in the treatment of HBV infections. ccc_R08 has been shown to be effective in the treatment of hepatitis C virus (HCV).
-
Alisol F
Alisol F is a natural product from Alisma plantago-aquatica Linn and has many activities.Alisol F shows anti-inflammatory activities and liver protection through the inhibition of MAPK, STAT3, and NF-κB activation in vitro and in vivo, it suppresses iNOS induction.
